By Fineline Cube 
Wuhan-based iRegene Therapeutics, a pioneer in AI-powered, chemically induced cell therapies, has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series B+ financing round. The round was led by FC Capital, with participation from Lotus Lake Capital, bringing the company’s total funding to over RMB 200 million (USD 27.4 million) in less than six months—a new high for financing in China’s iPSC field.
Financing Details and Industry Significance
The latest funding round underscores iRegene’s position as a leader in the rapidly growing iPSC sector in China. The capital will be used to advance the company’s innovative pipeline, including its core product NouvNeu001, the world’s first chemically induced universal cell therapy to enter clinical trials. The investment highlights growing investor confidence in regenerative medicine and AI-driven therapeutic approaches.
Pipeline and Technology Highlights
Founded in 2017, iRegene Therapeutics specializes in regenerative medicine, leveraging small-molecule chemical transcriptional regulation to induce pluripotent stem cells (iPSCs). In August 2023, the company achieved a significant milestone with the approval of Phase I/II studies for NouvNeu001 in China. This breakthrough positions iRegene at the forefront of global innovation in chemically induced cell therapies.-Fineline Info & Tech